Table 2 Comparison of factors between the non- and frailty groups in the Ehime study.

From: Novel modified frailty index predicts completion of adjuvant chemotherapy in resectable pancreatic cancer in a dual center study

Variables

Frailty ( +)

(n = 37)

Frailty (-)

(n = 49)

P value

Sex (male)

22

18

0.049

Age

71 (56–85)

71 (47–84)

0.848

Surgical procedure

  

0.345

 Distal pancreatectomy

15

16

 

 Pancreatoduodenectomy

22

30

 

 Total pancreatectomy

0

3

 

POCs (CD over 3%)

12

11

0.333

Pathological stage

  

0.497

 I

6

12

 

 II

31

36

 

 III

0

1

 

NAC

9

15

0.629

 GS

1

3

 

 GnP

7

12

 

 G + RT

1

0

 

S-1 incomplete rate (%)

13 (35.1%)

4 (8.2%)

0.003

Severe AEs (%)

15 (40.5%)

3 (6.1%)

 < 0.001

  1. POCs Postoperative complications, CD Clavien–Dindo classification, NAC Neoadjuvant chemotherapy, AEs Adverse events, G Gemcitabine, S S-1, nP nab-paclitaxel, RT Radiation therapy.
Back to article page